22 Comments
 

Yes, Aebersold and Sorenson (NY RX) left to ROTH (probably poached by Andrew Yearley, who himself left LAZ ~a year ago). At this point, only the legacy is really left at LAZ RX.

They are definitely not tier 1 (PJT RSSG, EVR RX) or even tier 2 (HL RX, MOE). They are probably somewhere with PWP, GHL, or GUGG (which is still great obviously, but considering that LAZ RX was often touted in the past as a tier 1 shop (alongside BX/PJT), it's a big fall)  

 

Exits are still good from what I hear (TPG, Apollo, Searchlight...). Talent though is weak, especially at the senior level. Overall, not the place to be. It's amazing how this group has fallen over the last 3-5 years - Used to dominate the RX scene next to PJT/BX. Now it's below the likes of MOE and EVR RX, probably in line PWP

 

have heard culture and WFH policy kinda sucks ass compared to rest of the Laz groups.

 

Take the credit shop. Worked across the table from Lazard and it does not look good. Other RX firms have much better deal flow and culture.

 
Most Helpful

Lot of misconceptions here, am pretty familiar with the group / situation. All the MDs who have left for Roths were underperforming / were pushed out, would not consider any of them to be meaningful. Think this is part of a firm-wide push to push out bad MDs and improve talent (if I recall they also hired a couple solid names in the distressed space to replace them). Couple news articles about this online

Have heard the nyc culture is alright, especially since those MDs have been pushed out. Believe exits are still quite strong, like someone else mentioned. Don’t know much about their Chicago office but think it’s pretty relaxed

 

Dunno man, the MDs they brought over aren't exactly stellar and frankly, when ~50% of your MD count leaves in a year it doesn't seem to be involuntary but rather an evacuation of a sinking ship

 

Agree with this...they had some major MDs leave in a mass exodus then the two MDs they brought in seem to be more creditor oriented. It's like...sure...we can't bring in any debtor mandates anymore because our platform has declined significantly so let's build out a creditor and UCC practice? I mean look at their background here: https://www.lazard.com/news-announcements/lazard-welcomes-two-new-manag…;

It will take a lot of time for Laz to be an industry leading Rx platform again, especially when other "T 2" shops are winning very solid mandates...

 

Lazard Rx is doing just fine… know the group directly. Def not pulling like 80% all debtor work any more, but still a very strong group.

 

At a different LAZ group, but the RX group is known to be a shitshow. Terrible culture with a shaky base. Exits are fine for now

 

Nihil sed ipsa facere praesentium quas et. Odit est quia autem minima id nulla et. Nesciunt quidem facere eius officiis. Placeat qui provident necessitatibus vel velit.

Quo accusantium aut sunt consequatur est qui. Perferendis fugiat incidunt culpa voluptas voluptatem quo quod. Quia illo placeat quos quas quas ducimus. Voluptas consequuntur fugit voluptate vel et animi. Quia minima ad vero at est.

 
Funniest

Nisi nihil consequatur eos ipsa in voluptatum perspiciatis ducimus. Veniam corporis ratione doloribus eos quidem numquam. Omnis eveniet labore minima inventore sint dignissimos. Molestiae sunt alias voluptas ipsum dignissimos deserunt ratione. Et exercitationem molestiae incidunt labore.

Rerum neque tempora voluptatibus facere vitae quas. A tempora iste natus aut qui ullam pariatur. Culpa provident atque voluptatem nihil non nisi ullam. Qui quam sunt doloribus ipsa quia. Sunt quis quis et consequatur quibusdam debitis. Excepturi doloremque et officiis iusto quia ut iste. Esse quam nihil vitae veritatis odio fuga.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Secyh62's picture
Secyh62
99.0
4
kanon's picture
kanon
99.0
5
DrApeman's picture
DrApeman
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”